Caribou Biosciences (NASDAQ:CRBU) Insider Ruhi Ahmad Khan Sells 6,938 Shares

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Ruhi Ahmad Khan sold 6,938 shares of Caribou Biosciences stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $1.96, for a total transaction of $13,598.48. Following the completion of the sale, the insider owned 104,998 shares in the company, valued at approximately $205,796.08. This represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Caribou Biosciences Trading Up 11.5%

NASDAQ CRBU opened at $2.14 on Wednesday. The company has a 50-day moving average price of $1.61 and a two-hundred day moving average price of $1.90. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.54. The stock has a market cap of $200.03 million, a price-to-earnings ratio of -1.26 and a beta of 2.61.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on CRBU shares. HC Wainwright boosted their price target on shares of Caribou Biosciences from $3.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Truist Financial set a $7.00 target price on Caribou Biosciences in a research report on Tuesday, November 4th. Citigroup raised their price target on shares of Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Caribou Biosciences currently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRBU. AQR Capital Management LLC boosted its position in shares of Caribou Biosciences by 741.6% in the first quarter. AQR Capital Management LLC now owns 525,878 shares of the company’s stock valued at $480,000 after acquiring an additional 463,391 shares during the period. Acadian Asset Management LLC acquired a new position in Caribou Biosciences during the 1st quarter valued at $61,000. Vanguard Personalized Indexing Management LLC raised its stake in Caribou Biosciences by 69.5% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company’s stock valued at $51,000 after purchasing an additional 16,736 shares during the last quarter. CWM LLC boosted its holdings in Caribou Biosciences by 53.5% in the 2nd quarter. CWM LLC now owns 33,839 shares of the company’s stock valued at $43,000 after purchasing an additional 11,798 shares during the period. Finally, Envestnet Asset Management Inc. grew its position in Caribou Biosciences by 626.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 318,657 shares of the company’s stock worth $402,000 after purchasing an additional 274,812 shares during the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.